


# THE Inside Story



American College of Gastroenterology (ACG) Conference, Las Vegas  
 Medical Director, Thomas Borody with Research Assistant, Sarah Finlayson

# CDD GOES International

## Inside ▶

CDD showcases Gastro advancements

GP Nights

Bioscience Opens Specialist Laboratory at CDD

Keeping Up With Technology


Recognition at LAST!!

# CDD Showcases Their Latest Gastro Advancements

Members of the Research Department recently represented the Centre at two international scientific meetings showcasing the latest advancements in the field of gastroenterology. Medical Director Thomas Borody attended the American College of Gastroenterology (ACG) Conference held in Las Vegas with Research Assistant Sarah Finlayson where three posters were presented to great response. One of these posters reported on a highly-effective antibiotic therapy developed at CDD for *Helicobacter pylori*. This 14-day rifabutin-based therapy

achieved successful eradication in 96% of patients compared to standard first-line treatments for *H. pylori* eradication which are increasingly ineffective. Importantly, this study was performed in a real-life patient setting rather than a controlled trial environment, making the results even more relevant.

Dr Antony Wettstein also presented a poster with Research Officer Jordana Campbell at the United European Gastroenterology Week held in Amsterdam. This poster described a novel treatment for *Blastocystis hominis*, a parasite capable





# Vitramed P/L Bioscience Opens Specialist Laboratory at CDD

A new research and development laboratory opened in October on the premises of CDD. The lab, belonging to Vitramed, promises opportunity to fast-track the development of CDD ideas in an 'in-house'-style environment. CDD also benefits from access to specialist laboratory equipment and complementary scientific expertise.

Since its inception in 2006, Vitramed has worked closely with CDD, supporting us with a product range that delivers benefits to our ability to diagnose, manage and treat gastrointestinal (GI) issues. This year, Vitramed established a new division, Vitramed Bioscience, following the joining of Dr Belinda Chapman, an experienced research microbiologist from the CSIRO.

The work of Vitramed Bioscience targets niche opportunities in GI-related science, especially microbiology. It is expected that the already successful relationship between CDD and Vitramed will be enhanced through Vitramed Bioscience. Current CDD projects utilising Vitramed Bioscience capabilities and the new lab at Five Dock include trials of novel detection procedures for *Mycobacterium avium paratuberculosis* (MAP), implicated in Crohn's disease, and a parasite, *Dientamoeba fragilis*.

Vitramed's new high powered microscope showing 1. 'Phase contrast and 2. bright-field (Giemsa stained) images of stool cultures'



## Keeping Up With Technology

To keep updated with the advancing art of endoscopy and improving patient outcome, the Centre has acquired the newest Olympus endoscopy system. These new scopes have the highest resolution and combined with the High Definition television screen they deliver the sharpest possible images to help physicians provide accurate screenings and diagnosis. They also

feature Narrow Band Imaging (NBI), Close Focus which both enhances observation of capillary and mucosal structures. Each colon scope has an auxiliary water channel which flushes away unwanted debris ensuring a clear view at all times. The ergonomically designed grip enhances scope maneuverability, while easy-to-access knobs with user selectable switches improve operability. The combination of all these technologies work together to enhance procedural efficiency and to help minimize patient discomfort.

Registered Nurse, Marcella Wong with CDD's new Olympus Endoscopy System



## Please welcome to the team our new staff for late 2011 and 2012

Vanessa Bregolin (Nursing), Rossana Bresolin (Nursing), Sarah Finlayson (Research), Annette Harvey (Reception), Patricia Kalfas (Reception), Munali Munali (Nursing), Laura Narain (Medications/Nursing), Leigh O'Connor (Technician).



### ANNETTE NELSON DON/CENTRE MANAGER

Annette started her nursing career in the Whyalla Base Hospital in South Australia. She has travelled and worked in Queensland, New South Wales and South Australia over the last 25 years. Her specialty over the last 9 years has been Gastroenterology - she is an

Australian Credentialed Gastroenterology Nurse (ACGEN). Annette has been warmly welcomed by the family at CDD and is enjoying the challenges of the busy centre.

We are sad to be saying goodbye to Dr Nisha Kendall at the end of January 2013. Dr Kendall has been with CDD for 5 years and has decided to spend more time with her family. It has been a pleasure to have her as one of our Drs and she will be missed by not only the CDD staff but her patients as well. We wish her all the best in the future.

# Breaking News....

## Recognition at LAST!

from The American College of Physicians [4th Dec 2012]

### Experts: Fecal transplant may become standard for C. diff

Within the next couple of years, fecal transplants could become the primary therapy for recurrent Clostridium difficile infections, according to CDC epidemiologist Dr. Cliff McDonald and other experts. Drugmakers also are working on treatments for C. diff, but Ontario physician Dr. Christine Lee says the more than 100 fecal transplant procedures she has done have resolved the condition and prevented recurrences in 90% of cases. [Reuters (11/30)]

The Centre for Digestive Diseases is the modern champion of Faecal Microbiota Transplantation [FMT], having performed more than 2,500 procedures over the past 18 years, often for recurrent C. difficile infection [CDI]. The epidemic strains of C. difficile which have caused thousands of deaths in the United States have now reached our shores, being reported in Perth, Melbourne and Sydney. CDD is the only Centre in Australia to routinely treat CDI with FMT. Consequently a number of extremely ill patients have been transferred to the Centre by ambulance for this potentially life-saving procedure. In these severe CDI patients, all experienced

a rapid return to health, despite previously being hospitalised or treated with numerous antibiotic courses for extended periods of time. This beneficial result has caused a number of hospitals to sit up and take notice with various centres all over the world now conducting clinical trials into FMT in CDI and other conditions. We have also seen the introduction of FMT into worldwide Gastroenterology Conferences as well as emergence of abstracts and posters on the topic from other centres. CDD is proud that after decades of defending FMT, the medical world has taken notice and is trying to catch up. CDD again developed a ground breaking procedure and remains at the forefront.

The Centre has further been recognised internationally for this pioneering work, with Prof Lawrence Brandt and associates reporting a long-term follow-up study of patients treated with FMT for severe CDI at next year's Digestive Disease Week, including a number of patients treated at our Centre. Diarrhoea resolved in a staggering 75% of patients treated with FMT within 1-7 days (average 4.5 days) and a total of 92% of patients were cured of their CDI post-FMT after their first treatment.

Further refinements of this treatment are likely to be applied to Inflammatory Bowel Disease and other conditions.



#### We have medications to treat:

- Resistant Helicobacter pylori
- Intestinal Parasites
  - o Blastocystis Hominis
  - o Dientamoeba Fragilis
  - o Others
- Clostridium difficile
- Crohn's Disease
- Constipation
- Irritable Bowel Disease

You can download protocols for treatments, and obtain medication information that is used in the protocols.

**TGA - SAS Category B Form approval is NOT required for compounded medications.**

#### How to order:

**1.** Phone **2.** Fax **3.** Email a request to [scc@pharmacy4u2c.com.au](mailto:scc@pharmacy4u2c.com.au) **4.** Walk in and collect  
Please note that all original prescriptions will need to be given or posted to SCC prior to medications leaving SCC.

**Successful treatments for resistant H.pylori and Parasite infections available - call us!**

Shop 143 Carlingford Court, Carlingford NSW 2118  
Ph: 61-2-9871 7533 Fax: 61-2-9873 5699

**Visit [www.sydneycompounding.com](http://www.sydneycompounding.com)**

*To our patients, referring Doctors and Specialists, staff and friends. CDD would like to take this opportunity to wish you all the best of health, a Merry Xmas, and a prosperous New Year.*

# CDD The Centre for Digestive Diseases

Level 1, 229 Great North Road, Five Dock NSW 2046

ABN 54 097 085 884

Phone: 61 2 9713 4011 Fax: 61 2 9712 1675

For more information visit: [www.cdd.com.au](http://www.cdd.com.au)

PLEASE NOTE: The information contained in this newsletter is of a general nature only and may not be applicable to any individual person or situation. This information must not be relied upon nor substituted for qualified medical advice. Any statements, predictions or representations relating to outcomes, side effects or efficacy of any treatment or course of action are indicative in nature only and cannot be applied to any particular person or situation. Should you require further information on anything contained in this newsletter, please contact CDD or your local GP.

© 2012 Centre for Digestive Diseases. All rights reserved. Unauthorised reproduction is prohibited. All trade marks referred to in this publication are the property of their respective owners.